Acute Myelogenous Leukemia (AML) Clinical Trial
Official title:
Omacetaxine for Consolidation and Maintenance in Patients Age ≥ 55 With AML in First Remission: A Pilot Study
The purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (AML) in first complete remission following induction with cytarabine and an anthracycline, and also to assess the safety and tolerability of omacetaxine for maintenance in patients age 55 and older with acute AML in first complete remission following 3 consolidation courses with omacetaxine.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT01451437 -
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)
|
Phase 1 | |
| Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
| Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 | |
| Completed |
NCT00088543 -
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
|
N/A | |
| Recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Terminated |
NCT01113502 -
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00943553 -
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
|
Phase 2 | |
| Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
| Terminated |
NCT00672152 -
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
|
Phase 1 | |
| Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
| Terminated |
NCT02200380 -
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
|
Phase 2 | |
| Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
| Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
| Terminated |
NCT00779480 -
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
|
Phase 1 | |
| Completed |
NCT01768845 -
Unrelated Umbilical Cord Blood (UBC)Transplantation
|
N/A | |
| Terminated |
NCT01265199 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
| Completed |
NCT02793544 -
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 |